Rtw Investments Adds $6M in Apogee Therapeutics, Inc. ($APGE)

RTW Investments has increased its stake in Apogee Therapeutics, Inc. (NasdaqGM: APGE) by 70,000 shares, bringing its total holdings to approximately 2.78 million shares. The value of this position is about $245.74 million, according to the latest Form 13F filing with the SEC for the reporting period.

What Changed in RTW Investments' Apogee Therapeutics Position

RTW Investments boosted its position in Apogee Therapeutics by adding 70,000 shares, representing a 2.58% increase from the previous quarter. The fund now holds a total of 2,782,097 shares, reflecting a strong vote of confidence in the biotechnology company.

Other Institutional Activity in Apogee Therapeutics

Other major institutional investors have also been active in Apogee Therapeutics. T. Rowe Price Investment Management, Inc. significantly increased its holdings by 7,568,528 shares, ending with 10,300,984 shares valued at approximately $867.03 million. FMR LLC added 1,037,253 shares, bringing its total to 9,262,291 shares worth about $779.61 million. Meanwhile, Wellington Management Group LLP reduced its stake by 370,882 shares, now holding 4,375,703 shares valued at $368.30 million. BlackRock, Inc. also increased its position by 301,657 shares, totaling 4,085,651 shares valued at $343.89 million.

Apogee Therapeutics Stock Snapshot

Shares of Apogee Therapeutics (NasdaqGM: APGE) are trading near $88.33. The company has a market capitalization of approximately $6.66 billion and a forward P/E ratio that is not meaningful due to a lack of profitability. With a beta of 0.619, the stock has traded between a 52-week low of $34.34 and a high of $95.32. Its 50-day moving average is $84.45, and the 200-day moving average is $68.37.

Insider Buying and Selling at Apogee Therapeutics, Inc.

Recent insider transactions at Apogee Therapeutics include CEO Michael Thomas Henderson selling 20,000 shares on June 10, 2026, at an average price of $83.38 as part of a planned sale under Rule 10b5-1. Additionally, several insiders, including Mark McKenna and William Jones Jr., each acquired 7,657 shares on June 9, 2026.

Analysts Set New Price Targets

On June 8, 2026, RBC Capital maintained its 'hold' rating on Apogee Therapeutics with a price target of $97. Earlier, on May 27, 2026, Truist Securities also maintained a 'hold' rating with an $81 target, while Wedbush reiterated a 'buy' rating with a $135 target. The consensus among analysts is a 'strong buy', with a mean price target of $119.50.

About Apogee Therapeutics

Apogee Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing novel biologics for treating inflammatory and immunology-related conditions, including atopic dermatitis and asthma. Led by CEO Dr. Michael Thomas Henderson, the company is advancing several treatments through clinical trials, including Zumilokibart (APG777) for atopic dermatitis and asthma.

Bottom Line

RTW Investments' recent increase in its stake in Apogee Therapeutics signals continued interest in the company. Investors closely track these filings to gauge institutional confidence. However, it's important to remember that 13F filings are backward-looking and may not reflect current positions.